[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"anogenital-warts\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:anogenital-warts":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,56],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":33,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100568469","phase-2-effector-and-memory-immune-responses-to-hpv-vaccination-in-vietnamese-women-post-virus-exposure-100568469",false,"NCT06681636","Effector and Memory Immune Responses to HPV Vaccination in Vietnamese Women Post Virus Exposure","A Non-inferiority Study Comparing the Immunogenicity of a Standard or an Extended Three-dose Nonavalent Human Papillomavirus Vaccine Schedule Between High-risk Women Aged 18-26 Years and Age-matched Women in the General Population","HPV9vxFSW","Inclusion Criteria:\n\n* Is between the reporting ages of 18-26 years at the time of recruitment.\n* Engage in commercial sex in the last 6m (for FSW group) or have engaged in sexual activity (non-FSWs)\n* Willing and able to give written informed consent.\n* Willing to complete the follow-up requirements of the study.\n\nExclusion criteria\n\nParticipants meeting any of the following criteria will be excluded from the trial:\n\n* Pregnant or possibly pregnant\n* Has received any HPV vaccine previously\n* Has an axillary temperate greater than 38°C\n* Known allergies to any vaccine component\n* incapacity to provide consent\n* Currently receiving immunosuppressive medication or anti-cancer chemotherapy.\n* Known HIV infection.\n* Known Congenital immune deficiency syndrome.",true,"FEMALE","18 Years","26 Years",{"count":22,"type":23},300,"ESTIMATED","INTERVENTIONAL",[26],"PHASE2","A Study to evaluate if the 3 dose extended schedule (0-6-18 months) for the HPV vaccine Gardasil-9 provide similar immune responses and short term protection against HPV infection compared to the regular 3 dose schedule (0-2-6 months) in high risk women in Vietnam",[29,30,31,32],"HPV Infection","Cervical Cancer","Anogenital Cancer","Anogenital Warts",[34,35,36,37,38,39,40,41,42],"human papillomavirus","HPV vaccine","Vietnam","Female sex workers","immunogenicity","protection","extended schedule","HPV infection","cervical cancer","NOT_YET_RECRUITING","2024-11-07",{"date":46,"type":47},"2024-11-08","ACTUAL",{"date":49,"type":23},"2024-12-14",{"date":51,"type":23},"2027-12-31",{"name":53,"class":54},"National Institute of Hygiene and Epidemiology, Vietnam","OTHER",3,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":4,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":4,"studyType":24,"phases":68,"briefSummary":70,"conditions":71,"keywords":74,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":4},"100561236","phase-2-effectivity-of-protein-purified-derivative-treatment-for-anogenital-warts-in-hiv-patient-100561236","NCT06587542","Effectivity of Protein Purified Derivative Treatment for Anogenital Warts in HIV Patient","Comparison of the Response and Pathomechanism of Purified Tuberculin Unit Protein Injection Therapy for Anogenital Warts with and Without HIV Infection","Inclusion Criteria:\n\n1. Anogenital warts whose diagnosis is made based on anamnesis and physical examination, before receiving intralesional purified protein derivative injection therapy.\n2. All stored biological materials that have been previously taken through tissue from anogenital warts patients whose diagnosis was confirmed based on history and physical examination, 3 weeks after receiving the first intralesional purified protein derivative injection therapy.\n\nExclusion Criteria:\n\n* 1\\. With a history of allergies to purified protein derivative, generalized dermatitis, asthma and skin allergies 2. Currently taking immunosuppressant or immunomodulatory drugs based on the history and clinical examination.\n\n  3\\. Have an immunodeficiency disease based on anamnesis and clinical examination, except for HIV based on anamnesis, clinical examination and serological examination (anti-HIV).\n\n  4\\. Have a history of suffering from malignancy based on history and clinical examination.\n\n  5\\. Infected with tuberculosis based on history, clinical examination and chest radiography.\n\n  6\\. Infected with other STIs based on history, clinical examination, and serological examination (venereal disease research laboratory (VDRL), Treponema pallidum hemagglutination assay (TPHA), and Hepatitis B surface antigen (HBsAg)).","ALL","15 Years","60 Years",{"count":67,"type":23},30,[26,69],"PHASE3","Warts are a common viral infection of the skin and are prevalent throughout the world, with an overall prevalence in the United States estimated at 2-20%. The incidence of anogenital warts occurs more frequently in HIV-infected patients, with a seven-fold increase in risk compared to patients without HIV infection. Available treatments for anogenital warts can only reduce, but cannot eradicate, HPV infection. There are many therapeutic options for treating anogenital warts, but none can prevent recurrence. Immunotherapy has become one of the best therapeutic options for warts caused by HPV infection because it increases the immune response to HPV infection, resulting in remission, both in lesions that receive direct and indirect intralesional therapy. Immunotherapy, acts as a basic principle to enhance cell-mediated immunity for wart clearance. Apart from low recurrence, regression in immunotherapy for warts due to HPV infection generally occurs without cicatrices, so it is a consideration in choosing therapy, including anogenital warts. Various types of immunotherapy have been used, one of which is purified protein derivative, which can be used as an alternative therapy option for anogenital warts. In a previous case report, even though an HIV patient had an abnormal immune system, tuberculin protein purified derivative therapy, immunotherapy provided a significant clinical response in the form of a reduction in lesion size, compared to patients who were not given therapy. Research regarding the comparison of the response to tuberculin protein purified derivative therapy in anogenital warts patients with and without HIV infection has never been reported. Therefore, researchers are interested in examining the comparison of the response to tuberculin purified protein derivative therapy in anogenital warts patients between those with and without HIV infection and knowing the comparison of local and systemic cytokine changes when administering anogenital wart therapy with tuberculin protein purified derivative between those with and without HIV infection.",[32,72,73],"HIV Infection","Tuberculin Purified Protein Derivative",[75,76,77],"anogenital warts","HIV infection","tuberculin purified protein derivative","2024-09-16",{"date":80,"type":47},"2024-09-19",{"date":82,"type":23},"2024-09-15",{"date":84,"type":23},"2025-12-31",{"name":86,"class":54},"Universitas Padjadjaran"]